Target the Gene, Silence the Disease
RNAi technology makes it possible to target the genes that cause disease.
Treating diseases with significant unmet needs demands a unique approach at a fast pace—that’s exactly where we thrive. Our targeted RNAi molecule, TRiMTM, platform leverages a natural pathway to “silence” genes causing disease. With drug candidates in a growing number of disease areas, TRiMTM has shown it can target genes wherever they are.
What We Do Best
Acceleration
Every day we can save in our development timeline is one day earlier a person may benefit from our future therapies.
Collaboration
We go farther when we work together to reimagine how therapeutics are developed and delivered.
Growth
We don’t let uncertainty keep us from tackling big questions and finding meaningful solutions.
Watch How the TRiMTM Platform Works
Arrowhead has developed a therapeutic RNAi technology called TRiMTM—Targeted RNAi Molecule.
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLOTM (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Read the Press ReleaseContact Us
Corporate Headquarters
177 East Colorado Boulevard, Suite 700Pasadena, CA 91105
Research and Development
502 South Rosa RoadMadison, WI 53719
Research and Development
10102 Hoyt Park DriveSan Diego, CA 92131
Chemistry and Manufacturing
1080 Arrowhead WayVerona, WI 53593
Arrowhead Pharmaceuticals Ireland Limited
Registered in Dublin, Ireland (775949)3rd FloorOrmond Building31-36 Ormond Quay UpperDublin 7, D07 EE37, Ireland
Media
Kendy Guarinoni, PhD
LifeSci Communications
Call: 724-910-9389
kguarinoni@lifescicomms.com
Investors
Vince Anzalone, CFA
Arrowhead Pharmaceuticals, Inc.
Call: (626) 788 8035
ir@arrowheadpharma.com
Safety Reporting
To report an adverse event, please send an email to:
safety@arrowheadpharma.com
To report a product complaint, please send an email to:
productcomplaints@arrowheadpharma.com